Aptose Biosciences Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Note 17 - Subsequent Events (Details Textual)

Note 17 - Subsequent Events (Details Textual) - USD ($)						12 Months Ended
Note 17 - Subsequent Events (Details Textual) - USD ($)	Feb. 05, 2024	Jan. 31, 2024	Jan. 30, 2024	Jan. 01, 2024	Sep. 06, 2023	Dec. 31, 2023	Dec. 31, 2022	Mar. 26, 2024	Feb. 29, 2024	Nov. 04, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						217,000	420,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)						$ 9.87	$ 17.85
Future expense associated with option						$ 1,200,000
Common Stock, Shares Outstanding						7,942,363	6,157,749
Common shares issued upon exercise of stock options							$ 15,000
Common shares issued under the ESPP plan (Shares)						5,891	724
Common Stock [Member]
Common shares issued upon exercise of stock options							$ 26,000
Common shares issued under the ESPP plan (Shares)						6,000	1,000
Common Stock [Member] \| Warrant [Member]
Common warrants offering price		$ 1.71
Hanmi Pharmaceuticals [Member]
Issuance of common shares					$ 3,000,000
Number of common shares held						884,152				215,703
Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						169,000	352,000
Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						48,000	28,000
Share-Based Payment Arrangement, Tranche One [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%	50.00%
Share-Based Payment Arrangement, Tranche One [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%	50.00%
Share-Based Payment Arrangement, Tranche Two [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						16.67%	16.67%
Share-Based Payment Arrangement, Tranche Two [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%	25.00%
Share-Based Payment Arrangement, Tranche Three [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						16.67%	16.67%
Share-Based Payment Arrangement, Tranche Three [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%	25.00%
Share-based Payment Arrangement, Tranche Four [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						16.67%	16.67%
Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				408,168
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)				$ 2
Financing costs including underwriting costs, professional fees and recognition of deferred financing costs		$ 1,400,000
Common shares issued under the ESPP plan (Shares)	10,891
Subsequent Event [Member] \| Public Offering [Member]
Common shares issued (in shares)		5,649,122
Subsequent Event [Member] \| Over-Allotment Option [Member]
Common shares issued upon exercise of stock options		$ 736,842
Subsequent Event [Member] \| Keystone [Member] \| Common Stock [Member]
Common shares issued (in shares)				10,062
Subsequent Event [Member] \| Hanmi Pharmaceuticals [Member]
Warrants to purchase common shares, number of warrants		2,339,181						2,339,181
Warrants to purchase common shares, exchange price		$ 1.71						$ 1.71
Underwriting costs (as percent)		7.00%
Professional fees			$ 400,000
Subsequent Event [Member] \| Hanmi Pharmaceuticals [Member] \| Public Offering [Member]
Issuance of common shares		$ 4,000,000
Premium share price (as a percent)		11.00%
Common Stock, Shares Outstanding		15,706,810
Warrants outstanding		8,332,163
Subsequent Event [Member] \| Hanmi Pharmaceuticals [Member] \| Private Placement [Member]
Common shares issued (in shares)		2,105,263
Issuance of common shares		$ 9,700,000
Shares Issued, Price Per Share (in dollars per share)		$ 1.9
Subsequent Event [Member] \| Hanmi Pharmaceuticals [Member] \| Common Stock [Member]
Number of common shares held								2,989,414
Subsequent Event [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				388,170
Future expense associated with option				$ 402,000
Subsequent Event [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				19,998
Subsequent Event [Member] \| Share-Based Payment Arrangement, Tranche One [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				50.00%
Subsequent Event [Member] \| Share-Based Payment Arrangement, Tranche Two [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				16.67%
Subsequent Event [Member] \| Share-Based Payment Arrangement, Tranche Two [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				50.00%
Subsequent Event [Member] \| Share-Based Payment Arrangement, Tranche Three [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				25.00%
Subsequent Event [Member] \| Minimum [Member]
Private placement issuance percentage									20.00%